Phase III Clinical Study of JTE-052 - 52-week Long-term Study in Patients with Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-jRCT2080223500
- Lead Sponsor
- Japan Tobacco Inc.
- Brief Summary
This study confirmed that dermal application of JTE-052 ointment 0.5% twice daily for 52 weeks was safe and well tolerated in Japanese patients with atopic dermatitis. The efficacy in improving atopic dermatitis was maintained without attenuation during long-term application of JTE-052 ointment 0.5%.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 352
Inclusion Criteria
Patients with atopic dermatitis
Exclusion Criteria
Patients with active infection at the study drug application site
Use of topical corticosteroids (strongest or very strong) within 14 days before baseline
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method